CN107997174A - A kind of health composition and health food for having effects that to improve sleep and/or antidepression - Google Patents
A kind of health composition and health food for having effects that to improve sleep and/or antidepression Download PDFInfo
- Publication number
- CN107997174A CN107997174A CN201711336886.7A CN201711336886A CN107997174A CN 107997174 A CN107997174 A CN 107997174A CN 201711336886 A CN201711336886 A CN 201711336886A CN 107997174 A CN107997174 A CN 107997174A
- Authority
- CN
- China
- Prior art keywords
- parts
- health
- gaba
- extracts
- theanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000036541 health Effects 0.000 title claims abstract description 31
- 235000013402 health food Nutrition 0.000 title claims abstract description 22
- 230000000694 effects Effects 0.000 title abstract description 17
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 54
- 239000000284 extract Substances 0.000 claims abstract description 48
- 229940026510 theanine Drugs 0.000 claims abstract description 26
- 229940124277 aminobutyric acid Drugs 0.000 claims abstract description 14
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 238000009501 film coating Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 241000096284 Gynochthodes officinalis Species 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- OXIKLRTYAYRAOE-CMDGGOBGSA-N (e)-3-(1-benzyl-3-pyridin-3-ylpyrazol-4-yl)prop-2-enoic acid Chemical group N1=C(C=2C=NC=CC=2)C(/C=C/C(=O)O)=CN1CC1=CC=CC=C1 OXIKLRTYAYRAOE-CMDGGOBGSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 241001122767 Theaceae Species 0.000 claims 1
- VDGJOQCBCPGFFD-UHFFFAOYSA-N oxygen(2-) silicon(4+) titanium(4+) Chemical compound [Si+4].[O-2].[O-2].[Ti+4] VDGJOQCBCPGFFD-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 18
- 235000013305 food Nutrition 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- -1 GABA aminobutyric acids Chemical class 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 55
- 238000002474 experimental method Methods 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 29
- 241000256856 Vespidae Species 0.000 description 20
- 241000700159 Rattus Species 0.000 description 15
- 239000006188 syrup Substances 0.000 description 15
- 235000020357 syrup Nutrition 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000009182 swimming Effects 0.000 description 9
- 230000000147 hypnotic effect Effects 0.000 description 8
- 230000028527 righting reflex Effects 0.000 description 8
- 230000004620 sleep latency Effects 0.000 description 8
- 229960000796 barbital sodium Drugs 0.000 description 7
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 7
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 7
- 206010003084 Areflexia Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241001666377 Apera Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001229135 Nassa Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000012048 forced swim test Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to technical field of health care food, more particularly to a kind of health composition and health food for having effects that to improve sleep and/or antidepression.In parts by weight, which is made of 1~20 part of GABA aminobutyric acid, 1~30 part of theanine, 1~50 part of Rhizoma Gastrodiae extract and 1~80 part of Radix Morindae Officinalis extract.The technique effect that the present invention has is：After GABA aminobutyric acids, theanine, Rhizoma Gastrodiae extract and Radix Morindae Officinalis extract are used cooperatively by health composition of the present invention, there is significant synergistic function in terms of sleep and/or antidepression effect is improved.
Description
Technical field
It is more particularly to a kind of that there is to improve sleep and/or antidepression the present invention relates to technical field of health care food
Health composition and health food.
Background technology
Depression is also known as depressive disorder, low for main clinical characteristics with notable and lasting mental state, is mood disorder
Main Types.Clinical visible mental state is low unbecoming with its situation, and the downhearted of mood can be from depressed to extremely grieved, certainly
Inferior depression, in addition it is pessimistic and worldweary, can there are conamen or behavior；Even occur numb；Some cases have obvious anxiety and fortune
Dynamic property is intense；Severe patient may occur in which the psychotic symptoms such as illusion, vain hope.Somatization mainly has sleep-disorder, weak, appetite
Decline, weight loss, constipation, the pain at any position of body, sexual hypoesthesia, impotence, amenorrhoea etc..Sleep-disorder is mainly shown as
Early awakening, when generally early awakening 2~3 is small than usual, cannot fall asleep, this has characteristic meaning to paralepsy again after waking up.
Drug therapy is the primary treatment measure of moderate above paralepsy.Clinically the antidepressants of a line are main at present
Including selective serotonin reuptake inhibitor (SSRI, represent agents fluoxetine, Paxil, Sertraline, Fluvoxamine,
Citalopram and escitalopram), (SNRI, represents medicine text and draws for serotonin and norepinephrine reuptake inhibitors
Method is pungent and Duloxetine), norepinephrine and specific serotonin energy antidepressants (NaSSA, represents medicine Mirtazapine)
Deng.Traditional tricyclic antidepressants, tetracyclic antidepressants and monoamine oxidase inhibitors is since adverse reaction is larger, using substantially subtracting
It is few.
GABA aminobutyric acids (γ-aminobutyric acid) are a kind of naturally occurring nonprotein functional aminos, Yi Zhongtian
Right active ingredient, is the main inhibitory neurotransmitter of central nervous system, mediates nervous system rapid inhibitory effect, γ-ammonia
Base butyric acid is to study a kind of more deep important inhibitory neurotransmitter, it participates in a variety of metabolic activities, is had very high
Physiological activity., can also be anti-spiritual uneasy available for hepatic coma and dysbolism of brain, it is to anti-depression anxiety, improves mood, alleviation
Pressure, promote sleep, improve cerebration, a kind of pure natural substance that removing toxic substances is sobered up.
Theanine (L-Theanine) is distinctive free amino acid in tealeaves, and theanine is glutamic acid gamma-buserelin,
It is pleasantly sweet.Theanine is similar to intracerebral active material glutamine, glutamic acid on chemical constitution, is the master promoted the production of body fluid in tealeaves and moisten sweet tea
Want composition.Theanine can solution disappear fatigue, reduce blood pressure and improve ability of learning and memory.
Rhizoma Gastrodiae (scientific name：Gastrodia elata Bl.), also known as rhizoma gastrodiae, solely shake sesame, from it is female, close and superintended and directed from grass, god's grass, ghost
Postal, Mokpo, RHIZONA GASTRODIAE, wind grass, Bai Longpi etc., are orchid family Gastrodia herbaceos perennials.Its rhizome is used as medicine to treat
Have a dizzy spell, the disease such as extremity numbness, child convulsion, be rare Chinese medicine, treatment headache and insomnia is shared with Qiongzhen Ganoderma Lucidum.
Morinda officinalis (scientific name：Morinda officinalis How), it is dicotyledon Rubiaceae, main product is in Guangdong, wide
The ground such as west.Medicinal plant, cures mainly impotence and seminal emission, uterus cold infertile, irregular menstruation, few abdomen crymodynia, arthralgia pain due to rheumatism, muscles and bones impotence.
It yet there are no the report for being used cooperatively GABA- aminobutyric acids, theanine, Rhizoma Gastrodiae extract and Radix Morindae Officinalis extract
Road.
The content of the invention
In view of this, the present invention provides a kind of health composition and guarantor for having effects that to improve sleep and/or antidepression
Health food.After GABA- aminobutyric acids, theanine, Rhizoma Gastrodiae extract and Radix Morindae Officinalis extract are used cooperatively by the health composition,
There is significant synergistic function in terms of sleep and/or antidepression effect is improved.
In order to realize foregoing invention purpose, the present invention provides following technical scheme：
The present invention provides a kind of health composition, and in parts by weight, the health composition is by 1~20 part of GABA- amino
Butyric acid, 1~30 part of theanine, 1~50 part of Rhizoma Gastrodiae extract and 1~80 part of Radix Morindae Officinalis extract are made.
Preferably, in parts by weight, the health composition by 5~10 parts of GABA- aminobutyric acids, 5~25 parts of theanine,
10~35 parts of Rhizoma Gastrodiae extracts and 30~60 parts of Radix Morindae Officinalis extracts are made.
In a specific embodiment provided by the invention, in parts by weight, the health composition is by 5 parts of GABA- amino fourths
Acid, 25 parts of theanine, 30 parts of Rhizoma Gastrodiae extracts and 40 parts of Radix Morindae Officinalis extracts are made.
In another specific embodiment provided by the invention, in parts by weight, the health composition is by 10 parts of GABA- amino
Butyric acid, 25 parts of theanine, 35 parts of Rhizoma Gastrodiae extracts and 30 parts of Radix Morindae Officinalis extracts are made.
In another specific embodiment provided by the invention, in parts by weight, the health composition is by 10 parts of GABA- amino
Butyric acid, 20 parts of theanine, 10 parts of Rhizoma Gastrodiae extracts and 60 parts of Radix Morindae Officinalis extracts are made.
In another specific embodiment provided by the invention, in parts by weight, the health composition is by 5 parts of GABA- amino
Butyric acid, 5 parts of theanine, 30 parts of Rhizoma Gastrodiae extracts and 60 parts of Radix Morindae Officinalis extracts are made.
Present invention also offers the health composition to prepare the application in improving sleep and/or antidepression health food.
Present invention also offers a kind of health food, including health composition provided by the invention.
Preferably, the formulation of the health food is capsule, tablet, pulvis or granule.
Preferably, the formulation of health food is capsule, its raw material includes：1~10 part of GABA~aminobutyric acid, 5~
20 parts of theanine, 10~30 parts of Rhizoma Gastrodiae extracts, 10~30 parts of Radix Morindae Officinalis extracts, 10~30 parts of pregelatinized starch, 5~10 parts
Ac-Di-Sol, 1~5 part of magnesium stearate.
Preferably, the formulation of health food is tablet, its raw material includes：1~10 part of GABA~aminobutyric acid, 5~20
Part theanine, 10~30 parts of Rhizoma Gastrodiae extracts, 10~30 parts of Radix Morindae Officinalis extracts, 10~15 parts of microcrystalline celluloses, 5~10 parts of nothings
Water and milk sugar, 1~5 part of Ac-Di-Sol, 1~5 part of silica, 1~2 part of magnesium stearate, 0.5~1 part of brown are thin
Film coating powder.
The present invention provides a kind of health composition and health food for having effects that to improve sleep and/or antidepression.With
Parts by weight meter, the health composition by 1~20 part of GABA- aminobutyric acid, 1~30 part of theanine, 1~50 part of Rhizoma Gastrodiae extract and
1~80 part of Radix Morindae Officinalis extract is made.The technique effect that the present invention has is：Health composition of the present invention is by GABA- amino fourths
After acid, theanine, Rhizoma Gastrodiae extract and Radix Morindae Officinalis extract are used cooperatively, have in terms of sleep and/or antidepression effect is improved
There is significant synergistic function.
Embodiment
The invention discloses a kind of health composition and health food for having effects that to improve sleep and/or antidepression, sheet
Field technology personnel can use for reference present disclosure, be suitably modified technological parameter realization.In particular, it is all similar
Replace and change apparent to those skilled in the art, they are considered as being included in the present invention.The present invention's
Method and application are described by preferred embodiment, and related personnel can substantially not depart from present invention, spirit
Method described herein and application are modified or suitably changed with combining with scope, to realize and using skill of the present invention
Art.
Original used in the health composition and health food provided by the invention for having effects that to improve sleep and/or antidepression
Material or auxiliary material can be bought by market.Rhizoma Gastrodiae extract and Radix Morindae Officinalis extract are water extract, its extracting method is ability
Extracting method known to field technique personnel.
With reference to embodiment, the present invention is further explained：
Test example 1
(1) depressed animal experiment is improved
1.1 experimental animal
SPF grades of male SD rats, 180 ± 10g of weight are selected, animal is purchased from Guangdong Medical Lab Animal Center, tests
Animal uses credit number：SYXK (Guangdong) 2013-0002.
1.2 experiment packet
SD strains male rat 110, weight 200g or so.Animal training adapts to syrup before experiment, according to syrup preference
Degree is layered so that the degree distribution of every group of rat preference syrup is averaged.Experiment is divided into 11 groups, is respectively：Normal group,
Model group, positive controls Citalopram group, the first control group, the second control group, the 3rd control group, the 4th control group, first
Test group, the second test group, the 3rd test group, the 4th test group, every group 10.
Table 1 tests each group administration component
2 control group of table and test group administration composition proportion
1.3 test method
The raising of each group equal single cage, rats in normal control group are placed in other room, 5/cage, in identical room temperature, illumination
Under the conditions of normally feed, except syrup preference experiment and forced swim test before fasting, prohibit water in addition to, do not receive stimulation.Except normal right
Outer according to group, remaining each group prepares depression model using chronic unpredictable gentle stimulation (CUMS)+lonely foster mode.CUMS has
Body method is as follows：24h/ times fasting for solids and liquids, 4 degree of water are swum 5min/ times, bedding and padding humidity 8h/ times, and constraint cage fetters 2h/ times, hemostasis
Clamp tail 1min/ times, 36V electro photoluminescence 1min interval 30s totally 30 circulation/time, being given once daily 3 kinds according to table of random number stress.
Since 8 week old of rat, continued stimulus gives given the test agent intervention after 4 weeks, is continued for whole experiment terminating.
1.4 Testing index
1) syrup preference experiment (before intervention, intervening 15d, intervene 30d)：
After 24h fasting for solids and liquids, weigh in, while give the sucrose water 100mL and 1 bottle of 100mL of every 1 bottle 2% of animal
Pure water, observes animal in 1h and drinks sucrose solution amount, calculate syrup preference, compare each group syrup preference and whether there is
Difference：
Preference=(syrup consumption/total liquid-consumed) * 100%.
2) forced swimming test (before intervention, intervening 15d, intervene 30d)
Transparent cylindrical swim cylinder, high 45cm, diameter 20cm, 25 degrees Celsius of water temperature, detection rat since swimming into
Enter the time needed for motionless state.It whether there is difference the time required to comparing each group.
1.5 data statistical approach
Data useRepresent, statistical analysis is carried out using SPSS21.0 softwares.If measurement data data variance
Variance is neat after neat or converted, then using one-way analysis of variance, comparison among groups LSD methods, if heterogeneity of variance, data are converted
Variance is still uneven afterwards, and statistical analysis is carried out using rank sum test.Insolation level α=0.05.
1.6 results and analysis
1.6.1 Chronic Moderate imprevision stress be to the influence of rat syrup consumption：
Compared with blank group, model group rats syrup consumption significantly reduces, and has significant difference (P<0.01) mould, is illustrated
The modeling of type group success, compared with model group, positive group and control 1 group, control 2 groups of rat syrup consumptions also significantly increase, have
There is significant difference (P<0.01 or P<0.05) rats in test groups syrup consumption showed increased, has significant difference (P<
0.01).Illustrate that test group has the function that to increase syrup consumption.
3 Chronic Moderate imprevision of table stress be to the influence of rat syrup consumption
| Group | Number of animals | Syrup consumption (%) |
| Blank group | 10 | 75.50±9.35 |
| Model group | 10 | 27.63±5.71▲▲ |
| Positive group | 10 | 47.50±9.35** |
| Compare 1 group | 10 | 30.10±3.87 |
| Compare 2 groups | 10 | 28.27±4.56 |
| Compare 3 groups | 10 | 26.79±4.93 |
| Compare 4 groups | 10 | 30.12±5.78 |
| Test 1 group | 10 | 35.00±7.29* |
| Test 2 groups | 10 | 38.13±6.64* |
| Test 3 groups | 10 | 42.68±5.89** |
| Test 4 groups | 10 | 45.32±3.76** |
Note：Compared with blank control group,▲P<0.05,▲▲P<0.01；Compared with model group, * P<0.05, * * P<0.01.
1.6.2 Chronic Moderate imprevision stress be to the influence of forced swimming test dead time
Compared with blank group, the model group rats forced swimming dead time is obviously prolonged, and has significant difference (P<
0.05) modeling success, is illustrated.Compared with model group, the positive group rat forced swimming dead time is obviously shortened, and has statistics
Difference (P<0.05)；Compare 1 group, 2 groups of rat forced swimmings of control have the trend of shortening, but no difference of science of statistics (P ＞ 0.05),
The rats in test groups forced swimming dead time is obviously shortened, and has significant difference (P<0.05), illustrate that test group can improve greatly
Mouse as Chronic Moderate imprevision stress caused by the forced swimming test dead time.
4 Chronic Moderate imprevision of table stress be to the influence of forced swimming test dead time
| Group | Number of animals | Dead time (second) |
| Blank group | 10 | 85.13±12.79 |
| Model group | 10 | 123.50±18.54▲▲ |
| Positive controls | 10 | 98.63±11.49* |
| Compare 1 group | 10 | 109.13±11.95 |
| Compare 2 groups | 10 | 108.25±10.82 |
| Compare 3 groups | 10 | 114.13±15.44 |
| Compare 4 groups | 10 | 112.88±13.30 |
| Test 1 group | 10 | 102.75±17.29* |
| Test 2 groups | 10 | 104.00±16.59* |
| Test 3 groups | 10 | 102.75±12.50* |
| Test 4 groups | 10 | 100.75±12.17* |
Note：Compared with blank control group,▲P<0.05,▲▲P<0.01；Compared with model group, * P<0.05, * * P<0.01.
(2) sleeping animal experiment is improved
1.1 experimental animal
SPF grades of thorn property ICR mouse, 20 ± 2g of weight are selected, animal is purchased from Guangdong Medical Lab Animal Center, and experiment is dynamic
Thing uses credit number：SYXK (Guangdong) 2013-0002.
1.2 experiment packet
Reference《Health food is examined and assessment technique specification》Method in (2003 editions).By Healthy female ICR mouse, weight
18g~22g, 120, divides 3 batches to be used to test, when the 1st batch of animal is slept for direct sleep experiments and extension yellow Jackets
Between test, the 2nd batch of animal is tested for the hypnosis of yellow Jackets sub-threshold dose, and the 3rd batch of animal be used for barbital sodium sleep latency
Phase tests.
Experiment is divided into 9 groups, and every group of 20 animals, are respectively：Blank group, 1 group of control, 2 groups of control, 3 groups of control, control 4
Group, 1 group of experiment, 2 groups of experiment, 3 groups of experiment, 4 groups of experiment, by the oral gavages of 0.2mL/10gBW, negative control group gives equivalent
Solvent, daily gavage 1 time.
Table 5 tests each group administration component
6 control group of table and test group administration composition proportion
1.3 test method
According to the Ministry of Public Health《Health food is examined and assessment technique specification》(version in 2003) method carries out.Experiment sets 3 portions
Point：Extend the experiment of the yellow Jackets length of one's sleep, yellow Jackets sub-threshold dose hypnosis experiment and barbital sodium Sleep latency
Experiment.
1.3.1 direct sleep experiments：Observe after tested group of animal give given the test agent, it is molten that negative control group gives same volume
After agent, if sleep phenomenon occur.Sleep is using righting reflex loss as index.Such as more than 30s~60s cannot the person of righting, both recognized
For righting reflex loss, into sleep.Righting reflex recovers to be to awaken, and righting reflex loss is animal to this period is recovered
The length of one's sleep.Record control group and test sample group sleep number of animals and the length of one's sleep.
1.3.2 the experiment of the yellow Jackets length of one's sleep is extended：:Carry out on the basis of direct sleep experiments, such as directly sleep
Experiment sleep for feminine gender, then carries out extending the experiment of the yellow Jackets length of one's sleep.Preliminary experiment is first carried out before doing formal experiment, determines to make
Animal 100% falls asleep, but does not make the length of one's sleep long yellow Jackets dosage, and formal experiment (this experiment is done with this dosage
Dosage is：47mg/kg·BW).After animal last gives solvent and various concentrations given the test agent, occur peak effect before 10min~
15min, yellow Jackets are injected intraperitoneally to each group animal, and using righting reflex loss as index, can observation given the test agent extend
The yellow Jackets length of one's sleep.
1.3.3 the hypnosis of yellow Jackets sub-threshold dose is tested：Preliminary experiment is first carried out before doing formal experiment, determines amobarbital
The yellow Jackets maximum sub-threshold dose that sodium subthreshold hypnotic dosage, i.e. 80%~90% mouse righting reflex do not disappear.Animal end
It is secondary give solvent and various concentrations given the test agent after, occur peak effect before 10min~15min, to each group animal intraperitoneal injection penta
(this test dose is barbital sodium maximum subthreshold hypnotic dosage：29mg/kgBW), sleep number of animals in 30min is recorded (to right
Areflexia reaches more than 1min persons).
1.3.4 yellow Jackets Sleep latency is tested：Preliminary experiment is first carried out before doing formal experiment, determines to make animal
100% falls asleep, but does not make the dosage of the length of one's sleep long barbital sodium, is formally tested with this dosage.Animal last is given
After solvent and various concentrations given the test agent 10min~20min, to each group animal intraperitoneal injection barbital sodium, (this test dose is：
240mg/kgBW), using righting reflex loss as index, influence of the observation given the test agent to barbital sodium Sleep latency.
1.4 result judgement：
Extend the yellow Jackets length of one's sleep experiment, the hypnosis of yellow Jackets (or barbital sodium) sub-threshold dose experiment, bar
Being tested than appropriate sodium Sleep latency has two positives in three experiments, and is acted on without obvious directly sleep, can determine that the tested material
Sample has improvement sleep function effect.
1.5 statistical method
Data carry out statistical analysis using SPSS 17.0.The length of one's sleep is measurement data, and data are carried out using variance analysis
The data of abnormal or heterogeneity of variance are carried out appropriate variable and changed by statistics, after normal state is met or variance requires together, with turning
Data after changing are counted；If being still not up to normal state or the neat purpose of variance after variable conversion, use rank sum test instead and unite
Meter.Sleep number of animals is enumeration data, using chi-square criterion.
1.6 results and analysis
1.6.1 direct sleep experiments
Each test group gives given the test agent, after negative control group gives same volume solvent, it is observed that 30min, righting reflex
In the presence of not occurring sleep phenomenon.
Influence of 7 sample of table to direct sleep laboratory
| Group | Number of animals | Sleeping animal number | Sleep rate (%) |
| Blank group | 20 | 0 | 0 |
| Compare 1 group | 20 | 0 | 0 |
| Compare 2 groups | 20 | 0 | 0 |
| Compare 3 groups | 20 | 0 | 0 |
| Compare 4 groups | 20 | 0 | 0 |
| Test 1 group | 20 | 0 | 0 |
| Test 2 groups | 20 | 0 | 0 |
| Test 3 groups | 20 | 0 | 0 |
| Test 4 groups | 20 | 0 | 0 |
Note：Blank control group compares,▲P<0.05,▲▲P<0.01。
1.6.2 the experiment of the yellow Jackets length of one's sleep is extended
Compared with blank control group, the average length of one's sleep of 1,2 group of control and test group mouse slightly extends, wherein testing
The length of one's sleep of group mouse dramatically increases (P ﹤ 0.05) compared with the control group, and has statistical significance, i.e., test group is to penta
There is extension effect in mouse length of one's sleep that is averaged of calmine induction.
Influence of 8 sample of table to the extension yellow Jackets length of one's sleep
Note：Blank control group compares,▲P<0.05,▲▲P<0.01。
1.6.3 the hypnosis of yellow Jackets sub-threshold dose is tested
Compared with blank group, control group 1, control group 2, the sleep incidence of test group mouse are without substantially changeing, no statistics
Meaning (P ﹥ 0.05) is learned, therefore the mice sleep incidence that this product induces sub-threshold dose carbrital is without obvious effect.
Influence of 9 sample of table to yellow Jackets sub-threshold dose hypnosis test
Note：Blank control group compares,▲P<0.05,▲▲P<0.01。
1.6.4 yellow Jackets Sleep latency is tested
Compared with blank group, the average length of one's sleep of 1,2 group of control and test group mouse slightly extends, and wherein test group is small
Be averaged sleep latency and control group of mouse has and significantly shortens (P ﹤ 0.05), and has statistical significance.
Influence of the table 10 to the yellow Jackets Sleep latency time
Note：Blank control group compares,▲P<0.05,▲▲P<0.01。
1 capsule product formula of embodiment and technique
First, it is formulated (by weight)：
2nd, production technology：
1. weigh, stock：Weigh the GABA- aminobutyric acids of recipe quantity, theanine, Rhizoma Gastrodiae extract, Radix Morindae Officinalis extract,
Pregelatinized starch, Ac-Di-Sol and magnesium stearate, it is spare.
It is 2. total mixed：The above-mentioned material got ready is added in mixer, mixing 30 minutes to discharging after mixing.
3. filling：Uniformly mixed material is added in capsule filling machine, is filled with 0# Capsuleses, 400mg/, dress
Within ± 4.5%, disintegration time is less than 60 minutes for amount control.
4. bottling：Equipment is adjusted on request, capsule is loaded in 150ml browns, 60/bottle, drier 1 wraps.
3rd, amount and eating method：2 times a day, every time 2 bags, 150ml warm water is taken after mixing it with water.
2 tablet formula of embodiment and technique
First, it is formulated (by weight)：
2nd, production technology：
1. weigh, stock：Weigh the GABA- aminobutyric acids of recipe quantity, theanine, Rhizoma Gastrodiae extract, Radix Morindae Officinalis extract,
Microcrystalline cellulose, Lactis Anhydrous, Ac-Di-Sol, silica, magnesium stearate and brown film coating powder are (water-soluble
Property), it is spare.
It is 2. total mixed：The above-mentioned material got ready is added in mixer (except magnesium stearate and brown film coating powder), mixing
The magnesium stearate that formula ratio is added after 25 minutes mixes 5 minutes, uniformly discharges afterwards to mixture.
3. tabletting：Use elongated mould tabletting, 800mg/ pieces, hardness 22-27kg/cm2, it is ensured that tablet weight variation ±
Within 4.5%, disintegration time limited is less than 30 minutes, and checks slice, thin piece appearance at any time.
4. coating：It is coated using brown film coating powder (water solubility), weightening 3.63%, solid content 16%.
5. bottling：Equipment is adjusted on request, coating tablet is loaded in 150ml browns, 60 pieces/bottle, drier 1 wraps.
3rd, amount and eating method：2 times a day, 2 tablets once, swallows.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of health composition, it is characterised in that in parts by weight, by 1~20 part of GABA- aminobutyric acid, 1~30 part of tea ammonia
Acid, 1~50 part of Rhizoma Gastrodiae extract and 1~80 part of Radix Morindae Officinalis extract are made.
2. health composition according to claim 1, it is characterised in that in parts by weight, by 5~10 parts of GABA- amino
Butyric acid, 5~25 parts of theanine, 10~35 parts of Rhizoma Gastrodiae extracts and 30~60 parts of Radix Morindae Officinalis extracts are made.
3. health composition according to claim 1 or 2, it is characterised in that in parts by weight, by 5 parts of GABA- amino fourths
Acid, 25 parts of theanine, 30 parts of Rhizoma Gastrodiae extracts and 40 parts of Radix Morindae Officinalis extracts are made.
4. health composition according to claim 1 or 2, it is characterised in that in parts by weight, by 10 parts of GABA- amino
Butyric acid, 25 parts of theanine, 35 parts of Rhizoma Gastrodiae extracts and 30 parts of Radix Morindae Officinalis extracts are made.
5. health composition according to claim 1 or 2, it is characterised in that in parts by weight, by 10 parts of GABA- amino
Butyric acid, 20 parts of theanine, 10 parts of Rhizoma Gastrodiae extracts and 60 parts of Radix Morindae Officinalis extracts are made.
6. any one of claim 1 to 5 health composition answering in improvement sleep and/or antidepression health food is prepared
With.
7. a kind of health food, it is characterised in that including any one of claim 1 to 5 health composition.
8. health food according to claim 7, it is characterised in that the formulation of the health food for capsule, tablet,
Pulvis or granule.
9. health food according to claim 8, it is characterised in that the formulation of the health food is capsule, it is former
Material includes：1~10 part of GABA~aminobutyric acid, 5~20 parts of theanine, 10~30 parts of Rhizoma Gastrodiae extracts, 10~30 parts of Morinda officinalis
Extract, 10~30 parts of pregelatinized starch, 5~10 parts of Ac-Di-Sols, 1~5 part of magnesium stearate.
10. health food according to claim 8, it is characterised in that the formulation of the health food is tablet, its raw material
Including：1~10 part of GABA~aminobutyric acid, 5~20 parts of theanine, 10~30 parts of Rhizoma Gastrodiae extracts, 10~30 parts of Morinda officinalis carry
Take thing, 10~15 parts of microcrystalline celluloses, 5~10 parts of Lactis Anhydrouses, 1~5 part of Ac-Di-Sol, 1~5 part of titanium dioxide
Silicon, 1~2 part of magnesium stearate, 0.5~1 part of brown film coating powder.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711336886.7A CN107997174B (en) | 2017-12-14 | 2017-12-14 | Health composition and health food with sleep improving and/or antidepressant effects |
| PCT/CN2018/111880 WO2019114428A1 (en) | 2017-12-14 | 2018-10-25 | Health-care composition and health-care food having efficacy of improving sleep and/or resisting depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711336886.7A CN107997174B (en) | 2017-12-14 | 2017-12-14 | Health composition and health food with sleep improving and/or antidepressant effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107997174A true CN107997174A (en) | 2018-05-08 |
| CN107997174B CN107997174B (en) | 2021-05-04 |
Family
ID=62058823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711336886.7A Active CN107997174B (en) | 2017-12-14 | 2017-12-14 | Health composition and health food with sleep improving and/or antidepressant effects |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107997174B (en) |
| WO (1) | WO2019114428A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125617A (en) * | 2018-09-30 | 2019-01-04 | 昭通市天麻研究院 | A kind of Rhizoma Gastrodiae composition being effectively improved sleep and preparation method, preparation and application |
| WO2019114428A1 (en) * | 2017-12-14 | 2019-06-20 | 汤臣倍健股份有限公司 | Health-care composition and health-care food having efficacy of improving sleep and/or resisting depression |
| CN113749253A (en) * | 2021-09-24 | 2021-12-07 | 李红光 | Food with functions of improving sleep and resisting depression |
| CN114081175A (en) * | 2020-08-24 | 2022-02-25 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of sleep improvement product |
| CN114668148A (en) * | 2022-03-31 | 2022-06-28 | 山东金胜生物科技有限公司 | Health-care composition with nerve calming and sleep aiding effects and preparation method, health-care product and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001187742A (en) * | 1999-12-28 | 2001-07-10 | Eag Kk | Testosteron-5-alfa-reductase inhibitor |
| CN1695492A (en) * | 2004-05-10 | 2005-11-16 | 沙大年 | Health food for stabilizing and adjusting blood pressure and improving sleep, and preparation method |
| CN1850064A (en) * | 2006-02-26 | 2006-10-25 | 郭凌云 | Preparation for relieving stress symptom |
| JP2006296213A (en) * | 2005-04-15 | 2006-11-02 | Unitika Ltd | Composition obtained from asparagus |
| CN102030835A (en) * | 2010-11-03 | 2011-04-27 | 北京佗林医药科技有限公司 | Radix Morindae officinalis extract, preparation method and applications thereof |
| CN102423443A (en) * | 2011-12-27 | 2012-04-25 | 峨眉山天梁星制药有限公司 | Double-formula medicine used for treating insomnia, and preparation method thereof |
| CN106309605A (en) * | 2016-10-08 | 2017-01-11 | 广东太阳神集团有限公司 | Health-care food with sleeping improving function and preparation method thereof |
| CN107456531A (en) * | 2017-09-12 | 2017-12-12 | 江苏德和生物科技有限公司 | A kind of pharmaceutical composition, preparation and application that can improve sleep |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105902569B (en) * | 2016-05-26 | 2019-07-09 | 吉林省中韩动物科学研究院 | Improve the composition and its preparation method and application of sleep disturbance |
| CN107997174B (en) * | 2017-12-14 | 2021-05-04 | 汤臣倍健股份有限公司 | Health composition and health food with sleep improving and/or antidepressant effects |
-
2017
- 2017-12-14 CN CN201711336886.7A patent/CN107997174B/en active Active
-
2018
- 2018-10-25 WO PCT/CN2018/111880 patent/WO2019114428A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001187742A (en) * | 1999-12-28 | 2001-07-10 | Eag Kk | Testosteron-5-alfa-reductase inhibitor |
| CN1695492A (en) * | 2004-05-10 | 2005-11-16 | 沙大年 | Health food for stabilizing and adjusting blood pressure and improving sleep, and preparation method |
| JP2006296213A (en) * | 2005-04-15 | 2006-11-02 | Unitika Ltd | Composition obtained from asparagus |
| CN1850064A (en) * | 2006-02-26 | 2006-10-25 | 郭凌云 | Preparation for relieving stress symptom |
| CN102030835A (en) * | 2010-11-03 | 2011-04-27 | 北京佗林医药科技有限公司 | Radix Morindae officinalis extract, preparation method and applications thereof |
| CN102423443A (en) * | 2011-12-27 | 2012-04-25 | 峨眉山天梁星制药有限公司 | Double-formula medicine used for treating insomnia, and preparation method thereof |
| CN106309605A (en) * | 2016-10-08 | 2017-01-11 | 广东太阳神集团有限公司 | Health-care food with sleeping improving function and preparation method thereof |
| CN107456531A (en) * | 2017-09-12 | 2017-12-12 | 江苏德和生物科技有限公司 | A kind of pharmaceutical composition, preparation and application that can improve sleep |
Non-Patent Citations (5)
| Title |
|---|
| JIN-SUN HEO等: "Anti-epilepsy Effect of Methanol Extract of Morinda officinalis Augments Pentylenetetrazol-Induced Convulsion Behaviors", 《KOREAN J. PLANT RES.》 * |
| 张大禄: "《科学解读保健食品 选对吃好保健康》", 31 January 2016, 中国医药科技出版社 * |
| 蔡永敏: "《最新中药药理与临床应用》", 31 January 1999, 华夏出版社 * |
| 雅各布•泰特鲍姆等: "《击退万病》", 30 November 2016, 吉林科学技术出版社 * |
| 黄世敬: "《抗抑郁中药良方》", 28 February 2016, 金盾出版社 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019114428A1 (en) * | 2017-12-14 | 2019-06-20 | 汤臣倍健股份有限公司 | Health-care composition and health-care food having efficacy of improving sleep and/or resisting depression |
| CN109125617A (en) * | 2018-09-30 | 2019-01-04 | 昭通市天麻研究院 | A kind of Rhizoma Gastrodiae composition being effectively improved sleep and preparation method, preparation and application |
| CN114081175A (en) * | 2020-08-24 | 2022-02-25 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of sleep improvement product |
| CN113749253A (en) * | 2021-09-24 | 2021-12-07 | 李红光 | Food with functions of improving sleep and resisting depression |
| CN114668148A (en) * | 2022-03-31 | 2022-06-28 | 山东金胜生物科技有限公司 | Health-care composition with nerve calming and sleep aiding effects and preparation method, health-care product and application thereof |
| CN114668148B (en) * | 2022-03-31 | 2023-08-15 | 山东金胜生物科技有限公司 | Health care composition with effects of soothing nerves and aiding sleep as well as preparation method, health care product and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019114428A1 (en) | 2019-06-20 |
| CN107997174B (en) | 2021-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107997174A (en) | A kind of health composition and health food for having effects that to improve sleep and/or antidepression | |
| CN108671140B (en) | Composition for improving sleep and application thereof | |
| CN101361830A (en) | Chinese traditional medicine formulation for treating depression and its preparation method | |
| WO2022099527A1 (en) | Heart-nourishing and nerve-soothing pharmaceutical composition and method for preparation thereof and application thereof | |
| CN115429864B (en) | Traditional Chinese medicine composition for treating depression | |
| CN102335331A (en) | Traditional Chinese medicine composition for treating vesania and preparation method thereof | |
| CN105943651B (en) | A kind of Chinese medicine composition that treating premature ovarian failure and its application | |
| CN102302137A (en) | Health-care food for improving sleep | |
| TWI706785B (en) | Composition for tranquilizing the nerves and aiding sleep and its preparation method and application | |
| CN103705774A (en) | Compound composition with effect of treating depression as well as preparation method and application thereof | |
| CN104147518A (en) | Traditional Chinese medicinal capsule for treating depression and preparation method thereof | |
| CN108837073A (en) | A kind of essential oil of traditional Chinese medicine eye sticker improving sleep | |
| DE202004018534U1 (en) | Herbal composition for side-effect free treatment of depression, comprising herbs or herbal extracts for promoting blood flow and reducing coagulated blood levels, calming, sedation and flow of Qi | |
| CN106237268B (en) | It is a kind of to treat schizoid pharmaceutical composition and its application | |
| CN104383421A (en) | Pharmaceutical preparation for treating insomnia and dreaminess | |
| CN104383420A (en) | Preparation method of pharmaceutical preparation for treating insomnia and dreaminess | |
| CN104095938B (en) | A kind of Mongolian medicinal preparation of Cure of depression | |
| CN105412265A (en) | Ranunculi ternati radix extract and application thereof | |
| WO2020233459A1 (en) | Composition for improving memory and preparation method therefor | |
| CN1686514A (en) | Chinese medicinal preparation for treating anxietas, depression and its production method | |
| CN105055694B (en) | A kind of Chinese medicine preparation for the treatment of fire derived from stagnation of liver-QI type depression | |
| CN109549193A (en) | A kind of Chinese medicine compound prescription improves the health food and preparation method thereof of sleep | |
| CN104383449B (en) | Pharmaceutical composition for treating depression syndrome | |
| CN100415283C (en) | Medicine for resisting inflammation, contracting uterus and eliminating tumor and its prepn process | |
| CN107753628A (en) | A kind of Chinese medicine composition and preparation method for treating insomnia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |